TScan Therapeutics, Inc. (TCRX)
TCRX Stock Price Chart
Explore TScan Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TCRX price movements and trends.
TCRX Company Profile
Discover essential business fundamentals and corporate details for TScan Therapeutics, Inc. (TCRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Jul 2021
Employees
143.00
Website
https://www.tscan.comCEO
Gavin MacBeath
Description
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Financial Timeline
Browse a chronological timeline of TScan Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.29, while revenue estimate is $1.88m.
Earnings released on 6 May 2026
EPS came in at -$0.22 matching the estimated -$0.22, while revenue for the quarter reached $982.00k , missing expectations by -60.72%.
Earnings released on 4 Mar 2026
EPS came in at -$0.18 surpassing the estimated -$0.27 by +33.33%, while revenue for the quarter reached $2.57m , beating expectations by +5.40%.
Earnings released on 12 Nov 2025
EPS came in at -$0.28 surpassing the estimated -$0.35 by +20.00%, while revenue for the quarter reached $2.51m , beating expectations by +29.43%.
Earnings released on 12 Aug 2025
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $3.08m , beating expectations by +65.38%.
Earnings released on 6 May 2025
EPS came in at -$0.26 surpassing the estimated -$0.28 by +7.14%, while revenue for the quarter reached $2.17m , beating expectations by +100.09%.
Earnings released on 5 Mar 2025
EPS came in at -$0.29 falling short of the estimated -$0.27 by -7.41%, while revenue for the quarter reached $665.00k , missing expectations by -56.24%.
Earnings released on 12 Nov 2024
EPS came in at -$0.25 surpassing the estimated -$0.28 by +10.71%, while revenue for the quarter reached $1.05m , missing expectations by -10.54%.
Earnings released on 12 Aug 2024
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%, while revenue for the quarter reached $536.00k , missing expectations by -70.22%.
Earnings released on 13 May 2024
EPS came in at -$0.32 falling short of the estimated -$0.25 by -28.00%, while revenue for the quarter reached $566.00k , missing expectations by -85.76%.
Earnings released on 6 Mar 2024
EPS came in at -$0.21 surpassing the estimated -$0.30 by +30.00%, while revenue for the quarter reached $7.21m , beating expectations by +108.77%.
Earnings released on 9 Nov 2023
EPS came in at -$0.24 surpassing the estimated -$0.43 by +44.19%, while revenue for the quarter reached $3.89m , missing expectations by -12.66%.
Earnings released on 10 Aug 2023
EPS came in at -$0.51 surpassing the estimated -$0.76 by +32.89%, while revenue for the quarter reached $3.15m , missing expectations by -28.03%.
Earnings released on 10 May 2023
EPS came in at -$0.93 falling short of the estimated -$0.73 by -27.40%, while revenue for the quarter reached $6.80m , beating expectations by +39.72%.
Earnings released on 8 Mar 2023
EPS came in at -$0.78 falling short of the estimated -$0.73 by -6.85%, while revenue for the quarter reached $1.00k , missing expectations by -99.98%.
Earnings released on 9 Nov 2022
EPS came in at -$0.67 surpassing the estimated -$0.73 by +8.22%, while revenue for the quarter reached $3.36m , missing expectations by -14.43%.
Earnings released on 10 Aug 2022
EPS came in at -$0.63 surpassing the estimated -$0.76 by +17.11%, while revenue for the quarter reached $4.06m , beating expectations by +35.03%.
Earnings released on 9 May 2022
EPS came in at -$0.67 surpassing the estimated -$0.69 by +2.90%, while revenue for the quarter reached $3.02m , beating expectations by +9.64%.
Earnings released on 9 Mar 2022
EPS came in at -$0.38 surpassing the estimated -$0.73 by +47.95%, while revenue for the quarter reached $2.85m , missing expectations by -17.67%.
Earnings released on 10 Nov 2021
EPS came in at -$0.80 falling short of the estimated -$0.68 by -17.65%, while revenue for the quarter reached $2.41m , missing expectations by -64.02%.
Earnings released on 19 Aug 2021
EPS came in at -$7.69 falling short of the estimated -$2.87 by -167.94%, while revenue for the quarter reached $2.85m , beating expectations by +17.20%.
TCRX Stock Performance
Access detailed TCRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
